This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dendorfer, A. Articles by Dominiak, P. Search for Related Content PubMed PubMed Citation Articles by Dendorfer, A. Articles by Dominiak, P. Related Collections ACE/Angiotension receptors Other Stroke

(Hypertension. 2001;38:142.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Potentiation of Kinin Analogues by Ramiprilat Is Exclusively Related to Their Degradation

Andreas Dendorfer; Siegmund Reißmann; Sebastian Wolfrum; Walter Raasch; Peter Dominiak

From Medical University of Lübeck, Institute of Experimental and Clinical Pharmacology and Toxicology (A.D., S.W., W.R., P.D.), Lübeck; and Friedrich-Schiller-University Jena, Institute of Biochemistry and Biophysics (S.R.), Jena, Germany.

Correspondence to Dr A. Dendorfer, Medical University of Lübeck, Institute of Experimental and Clinical Pharmacology and Toxicology, Ratzeburger Allee 160, D-23538 Lübeck, Germany. E-mail dendorfe{at}medinf.mu-luebeck.de

Abstract— The potentiation of kinin actions represents a cardioprotective property of ACE inhibitors. Although a clear contribution to this effect is related to the inhibition of bradykinin (BK) breakdown, the high efficacy of potentiation and the ability of ACE inhibitors to provoke a B₂-receptor-mediated response even after receptor desensitization has also triggered hypotheses concerning additional mechanisms of kinin potentiation. The application of kinin analogues with enhanced metabolic stability for the demonstration of degradation-independent mechanisms of potentiation, however, has yielded inconsistent results. Therefore, the relation between the susceptibility of B₂-agonists to ACE and the potentiation of their actions by ACE inhibitors was investigated with the use of minimally modified kinin derivatives that varied in their degree of ACE resistance. The B₂-agonists BK, D-Arg-[Hyp³]-BK, [Hyp,³ Tyr(Me)⁸]-BK, [Phe⁵]-BK, [D-NMF⁷]-BK, and [Phe⁸(CH₂-NH)Arg⁹]-BK were tested for degradation by purified rabbit ACE and for their potency in contracting the endothelium-denuded rabbit jugular vein in the absence and presence of ramiprilat. Purified ACE degraded D-Arg-[Hyp³]-BK and [Hyp,³ Tyr(Me)⁸]-BK at 81% and 71% of BK degradation activity, respectively, whereas other peptides were highly ([Phe⁵]-BK) or completely ([D-NMF⁷]-BK, [Phe⁸(CH₂-NH)Arg⁹]-BK) resistant. The EC₅₀ of BK-induced venoconstriction (1.15±0.2 nmol/L) was reduced by a factor of 5.7 in the presence of ramiprilat. Likewise, D-Arg-[Hyp³]-BK and [Hyp,³ Tyr(Me)⁸]-BK were both significantly potentiated by a factor of 4.4, whereas the activities of the other agonists were not affected. Ramiprilat exerted no influence on the maximum contraction induced by any of the agonists. It is concluded that the potentiation of kinin analogues during ACE inhibition correlates quantitatively with the susceptibility of each substance to degradation by ACE. As such, no evidence of degradation-independent potentiating actions of ACE inhibitors could be obtained.

Key Words: bradykinin • angiotensin-converting enzyme • receptors, bradykinin • kinins • rabbits

This article has been cited by other articles:

				F. G. Pelorosso, A. V. Halperin, A. M. Palma, W. Nowak, A. E. Errasti, and R. P. Rothlin Neutral Endopeptidase Up-Regulation in Isolated Human Umbilical Artery: Involvement in Desensitization of Bradykinin-Induced Vasoconstrictor Effects J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 713 - 720. [Abstract] [Full Text] [PDF]

				I. Fleming Signaling by the Angiotensin-Converting Enzyme Circ. Res., April 14, 2006; 98(7): 887 - 896. [Abstract] [Full Text] [PDF]

				F. Enseleit, T.F. Luscher, and F. Ruschitzka Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A31 - A36. [Abstract] [PDF]